Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
Go back to Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease| AmerElite Solutions, Inc. New (NASDAQ: AMRX) | Delayed: 16.20 -0.14 (0.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.34 | 52 Week High | $0.19 | |||
| Open | $16.48 | 52 Week Low | $0.07 | |||
| Day High | $16.61 | P/E | N/A | |||
| Day Low | $16.18 | EPS | $-0.01 | |||
| Volume | 2,331,454 | |||||
